These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 23733802

  • 1. Possible prevention of tuberous sclerosis complex lesions.
    Kotulska K, Borkowska J, Jozwiak S.
    Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
    [Abstract] [Full Text] [Related]

  • 2. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP, Krueger DA.
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [Abstract] [Full Text] [Related]

  • 3. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [Abstract] [Full Text] [Related]

  • 4. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN.
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [Abstract] [Full Text] [Related]

  • 5. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [Abstract] [Full Text] [Related]

  • 6. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R, Coniglio A, Garaci F, Curatolo P.
    Ital J Pediatr; 2013 Sep 17; 39():57. PubMed ID: 24044547
    [Abstract] [Full Text] [Related]

  • 7. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
    Peces R, Peces C, Cuesta-López E, Pérez-Dueñas V, Vega-Cabrera C, Azorín S, Selgas R.
    Nephrol Dial Transplant; 2010 Nov 17; 25(11):3787-91. PubMed ID: 20663789
    [Abstract] [Full Text] [Related]

  • 8. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J, Dachowska I, Kotulska K, Baranska D, Fendler W, Jozwiak S, Mlynarski W.
    Pediatr Blood Cancer; 2015 Apr 17; 62(4):616-21. PubMed ID: 25557360
    [Abstract] [Full Text] [Related]

  • 9. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
    Doğan V, Yeşil Ş, Kayalı Ş, Beken S, Özgür S, Ertuğrul İ, Bozkurt C, Örün UA, Karademir S.
    J Trop Pediatr; 2015 Feb 17; 61(1):74-7. PubMed ID: 25344617
    [Abstract] [Full Text] [Related]

  • 10. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Niolat J, Jóźwiak S.
    PLoS One; 2016 Feb 17; 11(6):e0158476. PubMed ID: 27351628
    [Abstract] [Full Text] [Related]

  • 11. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
    Dill PE, De Bernardis G, Weber P, Lösch U.
    Pediatr Neurol; 2014 Jul 17; 51(1):109-13. PubMed ID: 24810875
    [Abstract] [Full Text] [Related]

  • 12. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S, Stein K, Kotulska K.
    Future Oncol; 2012 Dec 17; 8(12):1515-23. PubMed ID: 23231513
    [Abstract] [Full Text] [Related]

  • 13. Regression of a cardiac rhabdomyoma in a patient receiving everolimus.
    Tiberio D, Franz DN, Phillips JR.
    Pediatrics; 2011 May 17; 127(5):e1335-7. PubMed ID: 21464184
    [Abstract] [Full Text] [Related]

  • 14. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P.
    Pediatr Neurol; 2015 Mar 17; 52(3):281-9. PubMed ID: 25591831
    [Abstract] [Full Text] [Related]

  • 15. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B.
    Transplant Proc; 2009 Nov 17; 41(9):3677-82. PubMed ID: 19917366
    [Abstract] [Full Text] [Related]

  • 16. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
    Goyer I, Dahdah N, Major P.
    Pediatr Neurol; 2015 Apr 17; 52(4):450-3. PubMed ID: 25682485
    [Abstract] [Full Text] [Related]

  • 17. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
    Kenerson H, Dundon TA, Yeung RS.
    Pediatr Res; 2005 Jan 17; 57(1):67-75. PubMed ID: 15557109
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A, Brösse I, Wiemer-Kruel A, Wilken B, Kreuzaler P, Hahn A, Bernhard MK, van Tilburg CM, Hoffmann GF, Gorenflo M, Hethey S, Kaiser O, Kölker S, Wagner R, Witt O, Merkenschlager A, Möckel A, Roser T, Schlump JU, Serfling A, Spiegler J, Milde T, Ziegler A, Syrbe S.
    Orphanet J Rare Dis; 2019 May 03; 14(1):96. PubMed ID: 31053163
    [Abstract] [Full Text] [Related]

  • 19. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.
    Rev Neurol; 2014 Dec 01; 59(11):497-502. PubMed ID: 25418144
    [Abstract] [Full Text] [Related]

  • 20. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
    Sadowski K, Kotulska K, Jóźwiak S.
    Pharmacol Rep; 2016 Jun 01; 68(3):536-42. PubMed ID: 26891243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.